Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)

v3.20.1
Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)
3 Months Ended
Mar. 31, 2020
Policies  
Research and Development

Research and Development

 

Research and development costs are expensed as incurred. The Company's research and development costs consist of internal costs and external clinical study expenses. These consist of salaries, fees, charges, and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. Research and development costs were approximately $1,576,000 and $366,000 for the quarters ended March 31, 2020 and 2019, respectively.